Alexander Rothman, PhD, on the Effects of IL-1β Inhibition With Canakinumab on BP and Hypertension

 

In this podcast, Alexander Rothman, MD, PhD, discusses his team's latest analysis of CANTOS, which evaluated whether interleukin-1β inhibition would reduce blood pressure, prevent incident hypertension, and modify relationships between hypertension and cardiovascular events.

Additional Resources:

  • Rothman AMK, MacFadyen J, Thuren T, et al. Effects of interleukin-1β inhibition on blood pressure, incident hypertension, and residual inflammatory risk: a secondary analysis of CANTOS. Hypertension. 2020;75(2):477-482. https://doi.org/10.1161/HYPERTENSIONAHA.119.13642
  • Ridker PM, Everett BM, Thuren T, et al; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131. https://doi.org/10.1056/nejmoa1707914

 

Alexander Rothman, MD, PhD, is a Wellcome Trust Clinical Research Career Development Fellow and honorary consultant cardiologist at the University of Sheffield and Sheffield Teaching Hospital NHS Trust in the United Kingdom.

Submit Feedback

Name